INTRODUCTION AND OBJECTIVES: The Phoenix (PD) and
Stuttgart definitions (SD) are used to define biochemical recurrence (BCR) in patients after radiotherapy and High Intensity Focused Ultrasound treatment of organ-confined prostate cancer (PCa) respectively. However, these definitions have also been applied to follow patients who have undergone cryosurgery. We sought to identify predictors of BCR using the PD and SD criteria and evaluate each criterion 0 s ability to predict biopsy-proven recurrence in primary focal cryosurgery (PFC) patients.
METHODS: We performed a retrospective review of patients who underwent PFC at two tertiary care centers. Patients were followed with serial prostate specific antigen (PSA) tests. PSA levels, pre-and post-PFC biopsy Gleason scores, number of positive cores, and BCR (defined as: PD ¼ [PSA nadir + 2 ng/mL] and SD ¼ [PSA nadir + 1.2 ng/ mL]) were recorded. Patients who experienced BCR were biopsied, monitored carefully or treated at the discretion of the treating urologist. Cox proportional regression and survival analyses were performed to assess time to BCR using the PD and SD criteria.
RESULTS: Of 162 patients included [median (range) follow up: 36.6 (2.8-109.4) months] in the study, 64 (39.5%) and 98 (60.5%) experienced BCR based on PD and SD, respectively. On multivariate Cox regression analysis, the number of positive pre-PFC biopsy cores was an independent predictor of both PD (Hazard Ratio [HR]: 1.4, p¼0.001) and SD (HR: 1.3, p¼0.006) BCRs. Post-PFC PSA nadir was an independent predictor of BCR using the PD (HR: 2.2, p¼0.024) but not SD (HR: 1.4, p¼0.181) BCR. Survival analysis showed a 3-year BCR free survival of 55% and 36% for PD and SD respectively. Of those biopsied after BCR, 14/26 (53.8%) using the PD and 18/35 (51.4%) using the SD were found to have cancer (57.1% PD and 66.7% SD were clinically significant PCa).
CONCLUSIONS: Both the PD and the SD showed about a 50% biopsy-proven rate of recurrence after PFC. The number of positive cores on pretreatment biopsy appears to be a significant predictor of failure after PFC. The ideal definition of BCR after PFC remains to be elucidated. 
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INTRODUCTION AND OBJECTIVES:
Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer (PCa) aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. The technological improvement of multiparametric magnetic resonance imaging (mpMRI), 3D-ultrasound and software for image fusion in order to locate more accurately PCa foci provides an optimal technology combination for the ideal focal efficacy. We report the 6-months oncological and functional results of primary focal ablation high-intensity focused ultrasound (HIFU) after fusion biopsy diagnosis of PCa in a prospective cohort of patients.
METHODS: Single-center prospective evaluation of focal therapy for organ-confined PCa was performed from November 2015 through April 2016 using Focal-Oneâ device (EDAP TMS). PCa diagnosis and localization was done based on mpMRI and -3D ultrasoundtargeted fusion biopsy (Trinity, Koelis) plus standard biopsy. HIFU focal ablation using Focal-Oneâ device was carried out under general anesthesia to immobilize the target lesion. The MRI/US imaging fusion of the target area was transported directely from Trinity to Focal One through specific software for the treatment. Treatment oncologic outcomes were evaluated with PSA and mpMRI 6 months after treatment. Targeted fusion biopsy after HIFU treatment was performed only in mpMRI positive patients. Functional outcomes were assessed with validated questionnaires for genitourinary symptoms.
RESULTS: Forty-one patients underwent focal therapy and were included in the study. Mean age was 70 yr (55-79 yr). Mean PSA was 6.8 ng/ml (0.5-18). National Comprehensive Cancer Network low-, intermediate-, and high-risk disease was 29 (70,8%), 10 (24,4%), and 2 (5,8%), respectively. Mean pre-treatment prostate volume was 39,7 ml (14-66); Mean volume of tissue treated was 13,5 ml (4-30). In three patients a ThuLEP procedure was performed 2 months before HIFU. In thirty-three patients (80,3%) the catheter was removed in day 7 after e938 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
